BookSunit K. Singh, Jens H. Kuhn, editors.
Summary: This second volume of a two-volume set focuses on specific pathogens and their mechanisms of pathogenesis as well as diagnostics, therapeutics and various strategies in the event of biological attacks. This multidisciplinary book appeals to readers from various fields, including biodefense, biosafety & biosecurity, virology, neurology, molecular biology and genetic engineering, as well as infectious disease specialists. Further, the work is of interest to basic science and applied science research scholars and experts working in the area of high-consequence or select agent virology.
Contents:
Intro; Preface 1; Preface 2; Contents; About the Editors;
1: Neurotropic Viruses; 1.1 Introduction; 1.2 Arboviruses; 1.2.1 Alphaviruses; 1.2.1.1 Eastern Equine Encephalitis; 1.2.1.2 Western Equine Encephalitis Virus; 1.2.1.3 Venezuelan Equine Encephalitis Virus; 1.2.1.4 Potential as Biothreat Agents; 1.2.1.5 Medical Countermeasures; 1.2.2 Flaviviruses; 1.2.2.1 Japanese Encephalitis Serocomplex; Japanese Encephalitis Virus; West Nile Virus; 1.2.2.2 Tick-Borne Encephalitis Virus Serocomplex; 1.2.2.3 Potential as Biothreat Agents; 1.2.2.4 Medical Countermeasures; 1.2.3 Henipaviruses 1.2.3.1 Potential as Biothreat Agents1.2.3.2 Medical Countermeasures; 1.2.4 Lyssaviruses; 1.2.4.1 Potential as Biothreat Agent; 1.2.4.2 Medical Countermeasures; 1.3 Summary; References;
2: Overview of Human Viral Hemorrhagic Fevers; 2.1 Introduction; 2.1.1 Arenaviridae; 2.1.1.1 Old World Mammarenaviruses; 2.1.1.2 New World Mammarenaviruses; 2.1.2 Bunyavirales; 2.1.2.1 Hantaviruses; 2.1.2.2 Nairoviruses; 2.1.2.3 Phenuiviruses; 2.1.3 Filoviridae; 2.1.4 Flaviviridae; 2.2 Biodefense Considerations; References;
3: Variola Virus: Clinical, Molecular, and Bioterrorism Perspectives; 3.1 Introduction 3.2 Biological Warfare and Bioterrorism Concerns3.3 Virology; 3.3.1 Classification; 3.3.2 Morphology; 3.3.3 Genome; 3.3.4 Life Cycle; 3.3.5 Life Cycle: Entry; 3.3.6 Life Cycle: Early Gene Expression; 3.3.7 Life Cycle: DNA Replication; 3.3.8 Life Cycle: Intermediate and Late Gene Expression, Morphogenesis, and Dissemination; 3.4 Smallpox Clinical Illness; 3.4.1 Clinical Classification of Variola Major Infections; 3.4.1.1 Ordinary Type; 3.4.1.2 Modified Type; 3.4.1.3 Flat Type; 3.4.1.4 Hemorrhagic Type; 3.4.2 Clinical Classification of Variola Minor Infections; 3.5 Smallpox Pathogenesis 3.5.1 Viral Entry and Infection3.5.2 Viral Dissemination; 3.5.3 Clinical and Anatomic Pathology; 3.5.4 Smallpox Pathogenesis in Animals; 3.6 Diagnosis; 3.6.1 Clinical Diagnosis; 3.6.2 Laboratory Diagnosis; 3.7 Prophylaxis; 3.7.1 First-Generation Vaccines; 3.7.2 Second-Generation Vaccines; 3.7.3 Third-Generation Vaccines; 3.7.4 Fourth-Generation Vaccines; 3.7.5 Oral and Inactivated Vaccines; 3.7.6 Global Stockpile of Smallpox Vaccines; 3.8 Therapeutics; 3.8.1 Overview; 3.8.2 Passive Immunization; 3.8.3 DNA Synthesis Inhibitors; 3.8.4 Viral Maturation Inhibitors; 3.8.5 Viral Egress Inhibitors 3.8.6 Host-Directed Drugs and Other Drugs3.8.7 Prophylaxis and Therapeutics: Future Directions; 3.9 Summary/Conclusions; References;
4: Viral Therapeutics; 4.1 Introduction; 4.2 Inhibitors of Nucleic Acid Synthesis; 4.3 Recently Approved Substances and Substances for Provisional Use Against Potentially High Consequence Viral Infections; 4.4 Inhibitors of Virus Attachment to Host Cell Membrane and Membrane Receptors, Inhibitors of Cell Entry; 4.5 RNA-Silencing and Antisense Oligomer Therapy; 4.6 Phosphorodiamidate Morpholino Oligomers (PMOs); 4.7 Targeting Hemorrhagic Disease Components